BioLineRx Ltd. Stock News

BioLineRx (NASDAQ:BLRX) issued its earnings results on Wednesday. The biotechnology company reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.16) by $0.01, Fidelity Earnings reports. BLRX stock traded up $0.40 during midday trading on Friday, hitting $2.67. The stock had a trading volume of 95,296 shares, compared to its average volume of []

BioLineRx (NASDAQ:BLRX) issued its quarterly earnings results on Wednesday. The biotechnology company reported ($0.15) EPS for the quarter, topping analysts consensus estimates of ($0.16) by $0.01, Fidelity Earnings reports. Shares of NASDAQ BLRX opened at $2.27 on Friday. The business has a fifty day simple moving average of $2.72 and a 200 day simple moving []

BioLineRx (NASDAQ:BLRX) posted its quarterly earnings results on Wednesday. The biotechnology company reported ($0.15) EPS for the quarter, beating the Zacks consensus estimate of ($0.16) by $0.01, Fidelity Earnings reports. Shares of BLRX stock opened at $2.27 on Friday. BioLineRx has a 12-month low of $2.05 and a 12-month high of $6.34. The firms 50 []

This Pancreatic Beta-Cell Protection market report takes into account changing wealth creation, government regulations, competitive marketplace economic expansion studies, ownership structure, classifications sector growths, industry expertise and primacy, risk evaluation, marketing tactics, regional developments, and new technologies in the market.

BioLineRx Ltd. (BLRX) CEO Philip Serlin on Q3 2021 Results - Earnings Call Transcript

- Positive results from pharmacoeconomic cost effectiveness study of Motixafortide in stem cell mobilization support its use as standard of care in combination with G-CSF - - Pre-NDA meeting with FDA set for mid-December; NDA submission planned for H1 2022 - - Cash and cash equivalents at

BioLineRx Ltd. (BLRX) CEO Philip Serlin on Q2 2021 Results - Earnings Call Transcript

TEL AVIV, Israel, Aug. 18, 2021 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today reports its financial results for

TEL AVIV, Israel, Aug. 12, 2021 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, announced today it will release its u

Today, we have our "Double Down or Diversify" series. We have 13 new ideas that contributors have chosen for the second half of the contest.

On May 4, the company crossed successfully a crucial hurdle, putting it en-route toward getting an FDA approval as early as next year.

ASLN, BLRX, FLXN, ICMB, and MRNS have been added to the Zacks Rank #5 (Strong Sell) List on June 4, 2021.